Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants" through a cooperative agreement mechanism. This initiative aims to establish or continue longitudinal infant cohorts to investigate how initial and repeated natural influenza infections and vaccinations influence immune responses, ultimately guiding the development of effective influenza vaccines. The program has an estimated total funding of $9.6 million for fiscal year 2027, with individual awards capped at $3 million per year for up to five years, and is open to a diverse range of applicants, including domestic and foreign organizations. Interested parties should submit their applications by June 4, 2026, and can direct inquiries to imprintingNOFO@mail.nih.gov for further information.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.